

Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration

NCT04796545

Status	RECRUITING
Phase	Not Applicable
Sponsor	VisionCare, Inc.
Enrollment	76 participants

Key Eligibility Criteria

Inclusion (10)

- Be 55 years of age or older.
 - Have retinal findings of geographic atrophy or disciform scar with foveal involvement as determined by fluorescein angiography or OCT.
 - Have evidence of cataract.
 - Have best-corrected distance visual acuity (BCDVA) no better than 20/80 (0.6 LogMAR) and no worse than 20/800 (1.6 LogMAR) in both eyes.
 - Have adequate peripheral vision in the eye not scheduled for surgery, assessed by observation of ambulation.
- ... and 5 more (see full listing online)

Exclusion (28)

- Evidence of active choroidal neovascularization (CNV) on fluorescein angiography or OCT or were treated for CNV within the past six months.
 - Any ophthalmic pathology that compromises the patient's peripheral vision in the fellow eye.
 - A history of steroid-responsive rise in IOP, uncontrolled glaucoma, or preoperative IOP > 22 mm Hg.
 - Corneal guttata.
 - Known sensitivity to post-operative medications.
- ... and 23 more (see full listing online)

Locations (13 total)

UZ Brussel, Brussels, Belgium
Centre d'Ophtalmologie Paradis-Monticelli, Marseille, France
Hélios Ophtalmologie, Saint-Jean-de-Luz, Saint-Jean-de-Luz, France
... and 10 more locations

<https://clinicaltrials.gov/study/NCT04796545>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).